Lynn Quek
Research Fellow and Clinical Haematologist
I am a Research Fellow and Clinical Haematologist with a specialist interest in Myelodysplastic syndromes and Acute Myeloid Leukaemia (AML). These are oligoclonal myeloid malignancies where genetically distinct clones can result in differences in leukaemia cell function within individual patients. I am investigating how clonal heterogeneity affects the biology of leukaemia stem cells in MDS and AML, in particular response to novel anti-leukaemic therapies. I am integrating genomic and functional approaches, including single cell techniques to elucidate clonal structures, epigenetic and transcriptional heterogeneity. My research and clinical interest converge on the common goal to develop better therapies to MDS and AML patients.
Recent publications
-
TP53 mutation status divides myelodysplastic syndromes with complex karyotypes into distinct prognostic subgroups.
Journal article
Haase D. et al, (2019), Leukemia, 33, 1747 - 1758
-
Therapy-Related Myeloid Neoplasms with Balanced Chromosome Rearrangements Frequently Arise from Pre-Existing Clonal Haematopoiesis
Conference paper
Dillon R. et al, (2018), BLOOD, 132
-
Salvage chemotherapy and donor lymphocyte infusion induces durable remissions in AML relapsing following allogeneic stem cell transplantation
Conference paper
Lubowiecki M. et al, (2018), BONE MARROW TRANSPLANTATION, 53, 184 - 185
-
Clonal heterogeneity of acute myeloid leukemia treated with the IDH2 inhibitor enasidenib.
Journal article
Quek L. et al, (2018), Nat Med, 24, 1167 - 1177
-
Single-cell analysis reveals the continuum of human lympho-myeloid progenitor cells.
Journal article
Karamitros D. et al, (2018), Nat Immunol, 19, 85 - 97